<DOC>
	<DOCNO>NCT02791906</DOCNO>
	<brief_summary>Heart failure ( HF ) epidemic major burden US healthcare system . The common cardiovascular endpoint HF . Thus , novel intervention prevent HF CKD highly desirable . This study ass : variability response ISMN therapy ; degree change central hemodynamics cardiac endpoint analysis change LV mass , diffuse myocardial fibrosis , myocardial systolic diastolic function .</brief_summary>
	<brief_title>Targeting Central Pulsatile Hemodynamics Chronic Kidney Disease</brief_title>
	<detailed_description>This open label , parallel arm , randomize study ISMN without vitamin C improve exercise capacity LV remodel CKD . Twenty subject CKD enrol study three different daily dose SR-ISMN administered time accompany random administration vitamin C half subject ( 500 mg three time daily ) . Before administration SR-ISMN , baseline assessment perform . These include arterial tonometry , Doppler echocardiography , reflection magnitude measurement , bicycle exercise test , activity monitoring , cardiac MRI , 24-hour blood pressure monitoring , blood drawing . After assessment , dose 30 mg SR-ISMN administer daily ( either without vitamin C ) first week , 60 mg SR-ISMN second week , 120 mg third week . After week , blood pressure central hemodynamics assess . The third week visit also include bicycle exercise study initiate long term dose ( 60 120 mg ) SR-ISMN . In long-term phase , blood pressure hemodynamics assess 12-weeks post initiation study medication ( ) . After 24 week perform final assessment , include test perform baseline assessment . Enrollment take place Hospital University Pennsylvania Penn Presbyterian Medical Center .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Ascorbic Acid</mesh_term>
	<criteria>Chronic kidney disease stage 3 Elevated leave ventricular mass index LV posterior wall thickness &gt; 1.4 cm document clinically indicated echocardiographic MRI examination within previous 24 month electrocardiographic LV hypertrophy Stable medical therapy define addition , removal change dosage &gt; 100 % ACE inhibitor , angiotensin receptor blocker , betablockers , calcium channel blocker &gt; 30 day Current therapy ACE inhibitor , hydralazine statin , show reduce nitrate tolerance A clinically indicate stress test demonstrating significant myocardial ischemia within 1 year enrollment , follow coronary revascularization Rhythm sinus ( i.e. , atrial fibrillation ) Noncardiac condition limit life expectancy &lt; 1 year Current anticipate future need long act organic nitrate therapy Severe aortic mitral valve disease Hypertrophic cardiomyopathy Known infiltrative inflammatory myocardial disease ( amyloid , sarcoid ) Pericardial disease Primary pulmonary arteriopathy History myocardial infarction , unstable angina , percutaneous transluminal coronary angiography ( PTCA ) coronary artery bypass grafting ( CABG ) within 60 day , requirement either PTCA CABG time consent Resting heart rate ( HR ) &gt; 100 bpm A reduce LV ejection fraction ( EF &lt; 50 % ) Known severe liver disease ( AST &gt; 3x normal , alkaline phosphatase bilirubin &gt; 2x normal ) Allergy ISMN Current therapy phosphodiesterase inhibitor , sildenafil , vardanafil tadalafil Therapy rosiglitazone Current pregnancy positive urine pregnancy test ; woman become pregnant study discontinue trial Therapy warfarin History kidney stone History G6PD deficiency Systolic blood pressure &lt; 110 mmHg diastolic blood pressure &lt; 40 mmHg ; Contraindications cardiac MRI : ( ) Central nervous system aneurysm clip ; ( b ) Implanted neural stimulators ; ( c ) Implanted cardiac pacemaker defibrillator ; ( ) Cochlear implant ; ( e ) Ocular foreign body ( e.g . metal shaving ) ; ( f ) Other implanted medical device : ( e.g . drug infusion port ) ; ( g ) Insulin pump ; ( h ) Metal shrapnel bullet ; ( ) Claustrophobia ; ( j ) Extreme obesity render patient unable fit narrowbore scanner ; ( k ) Unwillingness patient undergo cardiac MRI .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Chronic Kidney Diseases</keyword>
	<keyword>Chronic Kidney Insufficiency</keyword>
	<keyword>Chronic Renal Diseases</keyword>
	<keyword>Chronic Renal Insufficiency</keyword>
	<keyword>Kidney Insufficiency , Chronic</keyword>
	<keyword>Cardiac Failure</keyword>
	<keyword>Congestive Heart Failure</keyword>
	<keyword>Heart Decompensation</keyword>
	<keyword>Heart Failure , Congestive</keyword>
	<keyword>Myocardial Failure</keyword>
</DOC>